{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:26:57Z","timestamp":1794864417413,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with interstitial lung disease (ILD) require regular physician visits and referral to specialist ILD clinics. Difficulties or delays in accessing care can limit opportunities to monitor disease trajectory and response to treatment, and the COVID-19 pandemic has added to these challenges. Therefore, home monitoring technologies, such as home handheld spirometry, have gained increased attention as they may help to improve access to care for patients with ILD. However, while several studies have shown that home handheld spirometry in ILD is acceptable for most patients, data from clinical trials are not sufficiently robust to support its use as a primary endpoint. This review discusses the challenges that were encountered with handheld spirometry across three recent ILD studies, which included home spirometry as a primary endpoint, and highlights where further optimisation and research into home handheld spirometry in ILD is required.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Abstract body<\/jats:title>\n                <jats:p>Rate of decline in forced vital capacity (FVC) as measured by daily home handheld spirometry versus site spirometry was of primary interest in three recently completed studies: STARLINER (NCT03261037), STARMAP and a Phase II study of pirfenidone in progressive fibrosing unclassifiable ILD (NCT03099187). Unanticipated practical and technical issues led to problems with estimating FVC decline. In all three studies, cross-sectional correlations for home handheld versus site spirometry were strong\/moderate at baseline and later timepoints, but longitudinal correlations were weak. Other issues observed with the home handheld spirometry data included: high within-patient variability in home handheld FVC measurements; implausible longitudinal patterns in the home handheld spirometry data that were not reflected in site spirometry; and extreme estimated rates of FVC change.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Home handheld spirometry in ILD requires further optimisation and research to ensure accurate and reliable FVC measurements before it can be used as an endpoint in clinical trials. Refresher training, automated alerts of problems and FVC changes, and patient support could help to overcome some practical issues. Despite the challenges, there is value in incorporating home handheld spirometry into clinical practice, and the COVID-19 pandemic has highlighted the potential for home monitoring technologies to help improve access to care for patients with ILD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02221-4","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T14:03:03Z","timestamp":1668175383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Toby M.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Schiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Axmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Belloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bengus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Uwe","family":"Kirchgaessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"2221_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/jcm5080066","volume":"5","author":"N Chaudhuri","year":"2016","unstructured":"Chaudhuri N, Spencer L, Greaves M, Bishop P, Chaturvedi A, Leonard C. A review of the multidisciplinary diagnosis of interstitial lung diseases: a retrospective analysis in a single UK specialist centre. J Clin Med. 2016;5:66.","journal-title":"J Clin Med"},{"key":"2221_CR2","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"2221_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12890-016-0171-y","volume":"16","author":"A-M Russell","year":"2016","unstructured":"Russell A-M, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients\u2019 perspectives of the disease and treatment. BMC Pulm Med. 2016;16:10.","journal-title":"BMC Pulm Med"},{"key":"2221_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1183\/13993003.01204-2015","volume":"47","author":"F Bonella","year":"2016","unstructured":"Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47:597\u2013606.","journal-title":"Eur Respir J"},{"key":"2221_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12931-019-1076-0","volume":"20","author":"N Hoyer","year":"2019","unstructured":"Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20:103.","journal-title":"Respir Res"},{"key":"2221_CR6","doi-asserted-by":"publisher","first-page":"0021-2019","DOI":"10.1183\/23120541.00124-2019","volume":"5","author":"CC Moor","year":"2019","unstructured":"Moor CC, Wijsenbeek MS, Balestro E, Biondini D, Bondue B, Cottin V, et al. Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Res. 2019;5:00214\u20132019.","journal-title":"ERJ Open Res"},{"key":"2221_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.chest.2020.04.019","volume":"158","author":"AW Wong","year":"2020","unstructured":"Wong AW, Fidler L, Marcoux V, Johannson KA, Assayag D, Fisher JH, et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the Coronavirus Disease 2019 pandemic. Chest. 2020;158:1069\u201378.","journal-title":"Chest"},{"key":"2221_CR8","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S2213-2600(20)30452-5","volume":"8","author":"G Nakshbandi","year":"2020","unstructured":"Nakshbandi G, Moor CC, Wijsenbeek MS. Home monitoring for patients with ILD during the COVID-19 pandemic and beyond. Lancet Respir Med. 2020;8:1172\u20134.","journal-title":"Lancet Respir Med"},{"key":"2221_CR9","doi-asserted-by":"publisher","first-page":"1602406","DOI":"10.1183\/13993003.02406-2016","volume":"50","author":"KA Johannson","year":"2017","unstructured":"Johannson KA, Vittinghoff E, Morisset J, Lee JS, Balmes JR, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50:1602406.","journal-title":"Eur Respir J"},{"key":"2221_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","volume":"194","author":"A-M Russell","year":"2016","unstructured":"Russell A-M, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, et al. Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194:989\u201397.","journal-title":"Am J Respir Crit Care Med"},{"key":"2221_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12931-018-0810-3","volume":"19","author":"CC Moor","year":"2018","unstructured":"Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS. A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers. Respir Res. 2018;19:105.","journal-title":"Respir Res"},{"key":"2221_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1164\/rccm.202002-0328OC","volume":"202","author":"CC Moor","year":"2020","unstructured":"Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Chavannes NH, et al. Home monitoring in patients with idiopathic pulmonary fibrosis: a randomized controlled trial. Am J Respir Crit Care Med. 2020;202:393\u2013401.","journal-title":"Am J Respir Crit Care Med"},{"key":"2221_CR13","doi-asserted-by":"publisher","first-page":"00054-2020","DOI":"10.1183\/23120541.00054-2020","volume":"6","author":"CC Moor","year":"2020","unstructured":"Moor CC, van den Berg CAL, Visser LS, Aerts JGJV, Cottin V, Wijsenbeek MS. Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. ERJ Open Res. 2020;6:00054\u20132020.","journal-title":"ERJ Open Res"},{"key":"2221_CR14","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1093\/rheumatology\/keaa607","volume":"60","author":"CC Moor","year":"2021","unstructured":"Moor CC, van Leuven SI, Wijsenbeek MS, Vonk MC. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. Rheumatology (Oxford). 2021;60:2467\u201371.","journal-title":"Rheumatology (Oxford)"},{"key":"2221_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","volume":"8","author":"TM Maher","year":"2020","unstructured":"Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8:147\u201357.","journal-title":"Lancet Respir Med"},{"key":"2221_CR16","doi-asserted-by":"crossref","unstructured":"Swigris JJ, Nathan SD, Tighe RM, Nagra S, Rabe C, Kelkhoff D, et al. STARMAP: An Observational Study to Assess Disease-Relevant Outcomes Using Home Monitoring Devices in Patients With Idiopathic Pulmonary Fibrosis (IPF). Presented at the Pulmonary Fibrosis Foundation Summit 2019; November 7\u20139, 2019; San Antonio, TX. PA1333 ed2019.","DOI":"10.1183\/13993003.congress-2019.PA1333"},{"key":"2221_CR17","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1007\/s12325-021-01790-y","volume":"38","author":"MS Wijsenbeek","year":"2021","unstructured":"Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor CC, Jouneau S, et al. Disease behaviour during the peri-diagnostic period in patients with suspected interstitial lung disease: the STARLINER study. Adv Ther. 2021;38:4040\u201356.","journal-title":"Adv Ther"},{"key":"2221_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12931-020-01524-8","volume":"21","author":"T Veit","year":"2020","unstructured":"Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, et al. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res. 2020;21:270.","journal-title":"Respir Res"},{"key":"2221_CR19","doi-asserted-by":"publisher","first-page":"2001518","DOI":"10.1183\/13993003.01518-2020","volume":"58","author":"I Noth","year":"2021","unstructured":"Noth I, Cottin V, Chaudhuri N, Corte TJ, Johannson KA, Wijsenbeek M, et al. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. Eur Respir J. 2021;58:2001518.","journal-title":"Eur Respir J"},{"key":"2221_CR20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1513\/AnnalsATS.201904-335RL","volume":"16","author":"V Marcoux","year":"2019","unstructured":"Marcoux V, Wang M, Burgoyne SJ, Fell CD, Ryerson CJ, Sajobi TT, et al. Mobile health monitoring in patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2019;16:1327\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"2221_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12325-018-0845-3","volume":"36","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek M, Bendstrup E, Valenzuela C, Henry MT, Moor C, Bengus M, et al. Design of a study assessing disease behaviour during the peri-diagnostic period in patients with interstitial lung disease: the STARLINER study. Adv Ther. 2019;36:232\u201343.","journal-title":"Adv Ther"},{"key":"2221_CR22","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/bmjresp-2018-000289","volume":"5","author":"TM Maher","year":"2018","unstructured":"Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res. 2018;5:e000289.","journal-title":"BMJ Open Respir Res"},{"key":"2221_CR23","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200:e70\u201388.","journal-title":"Am J Respir Crit Care Med"},{"key":"2221_CR24","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s11606-017-4082-2","volume":"32","author":"D Chaet","year":"2017","unstructured":"Chaet D, Clearfield R, Sabin JE, Skimming K, Council on Ethical and Judicial Affairs AMA. Ethical practice in Telehealth and Telemedicine. J Gen Intern Med. 2017;32:1136\u201340.","journal-title":"J Gen Intern Med"},{"key":"2221_CR25","doi-asserted-by":"crossref","unstructured":"Wijsenbeek M, Bendstrup E, Valenzuela C, Henry M, Bengus M, Gilberg F, et al. STARLINER Study: patients\u2019 and doctors\u2019 experiences with a digital eco-system. In: Presented at the virtual European Respiratory Society International Congress 2021. Poster 399 ed2021.","DOI":"10.1183\/13993003.congress-2021.PA399"},{"key":"2221_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12931-020-01377-1","volume":"21","author":"CC Moor","year":"2020","unstructured":"Moor CC, Kreuter M, Luppi F, Wuyts WA. The world is not enough\u2014the value of increasing registry data in idiopathic pulmonary fibrosis. Respir Res. 2020;21:105.","journal-title":"Respir Res"},{"key":"2221_CR27","doi-asserted-by":"publisher","first-page":"00405-2021","DOI":"10.1183\/23120541.00405-2021","volume":"7","author":"G Nakshbandi","year":"2021","unstructured":"Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res. 2021;7:00405\u20132021.","journal-title":"ERJ Open Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02221-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T14:07:30Z","timestamp":1668175650000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02221-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2221"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02221-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TMM has, via his institution, received industry-academic funding from AstraZeneca and GlaxoSmithKline R&D, and has received consultancy or speakers\u2019 fees from AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Fibrogen, Galapagos, GlaxoSmithKline R&D, IQVIA, Pliant, F. Hoffmann-La Roche, Ltd., Trevi and Veracyte.MK has received fees for speaking and\/or organising education from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, ERS, F. Hoffmann-La Roche, Ltd., GlaxoSmithKline and Novartis, has received fees for consulting from Boehringer Ingelheim, F. Hoffmann-La Roche, Ltd., Galapagos, GlaxoSmithKline, and InterMune, and has received research funding, including institutional funding, from Boehringer Ingelheim, BMBF, DFG, the German Center for Lung Research (DZL), F. Hoffmann-La Roche, Ltd., Dietmar Hopp Stiftung, InterMune, Lilly, Lungenfibrose e.V., medac Pharma, Olympus, UKGM and WATL.CCM has received unrestricted grants and speaker and\/or advisory board fees from Boehringer Ingelheim and F. Hoffmann-La Roche, Ltd. All grants and fees were paid to the Erasmus University Medical Center in Rotterdam, The Netherlands.SDN is a consultant and is on the speakers\u2019 bureau for F. Hoffmann-La Roche, Ltd. and Boehringer Ingelheim. His institution has received research funding from both companies. SDN is also a consultant for Bellerophon and United Therapeutics.JS is a paid consultant for Lung Therapeutics, an unpaid consultant for Boehringer Ingelheim, and has received grant support from Boehringer Ingelheim and Genentech, Inc.JA, MB and KUK are employees and shareholders of F. Hoffmann-La Roche, Ltd.PB and CS are employees of Genentech, Inc.FG is an employee of F. Hoffmann-La Roche, Ltd.MSW has received unrestricted grants and speaker fees from Boehringer Ingelheim and F. Hoffmann-La Roche, Ltd., and advisory board fees from BMS, Galapagos, Galecto, Horizon, NeRRe Therapeutics and Novartis. All grants and fees were paid to the Erasmus University Medical Center in Rotterdam, The Netherlands.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}